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Purpose: Recent advances in the understanding of  the biologic mechanisms of vascular 
diseases uggest that multifactorial stimulation of  the endothelial cell and its subsequent 
adhesion to leukocytes i a prerequisite to the formation of  atherosclerotic and restenotic 
lesions. As leukocyte-endothelial cell interaction is coordinated by a variety of  cell 
adhesion molecules (CAMs), we hypothesized that the expression of  certain CAMs is 
upregulated in the vasculature of  patients who have peripheral vascular disease. In 
addition, we proposed that insulin-like growth factor-1 (IGF-1) increases monocyte- 
endothelial adhesion by means of  upregulation of  these CAMs. 
Methods: Using immunohistochemical techniques, the expression of  intracellular adhesion 
molecule-1 (ICAM-1), vascular cell adhesion molecule-l(VCAM-1), E-selectin, and 
P-selectin was examined in human vascular disease specimens. Normal aortas obtained 
from the organ retrieval system were studied as control specimens. Adhesion studies 
between human umbilical vein endothelial cells (HUVECs) incubated with IGF-1 and 
purified human blood monocytes labeled with Slchromium were completed. Western 
blotting and flow cytometry were performed to show CAM expression on IGF- 1-treated 
HUVECs. 
Results: Of the CAMs, ICAM-1, P-selectin, and E-selectin were distinctly increased in 
diseased specimens when compared with control specimens (p < 0205). Adhesion studies 
showed an increase in monocyte-endothelial cel adhesion of  as much as 40% to 45% (p < 
0.01) over baseline, with peak adherence occurring 4 hours after treatment with IGF-1. 
IGF-1 increased adherence in a dose- and time-dependent manner. The threshold con- 
centration of  IGF-1 that induced increased adhesion was 20 ng/ml,  with a maximum 
effect occurring at 150 ng/ml.  This increased adhesion was attenuated by pretreatment 
with IGF-I  receptor antibody, as well as with genistein and herbimycin-A, which are 
potent and selective tyrosine kinase inhibitors. Increased adhesion correlated with an 
increase in the expression of  CAMs on the surface of  the HUVECs. An additive effect on 
adhesion was observed between IGF-1 and tumor necrosis factor-~t (TNF-~) and endo- 
thelin- 1 (ET- 1). Finally, immunohistochemical analysis of  human vascular disease speci- 
mens revealed an increased expression of  IGF-1 receptors as compared with control 
specimens (p < 0.05). 
Conclusions: These results suggest hat IGF-1 may be important in the pathogenesis of  
peripheral vascular disease by increasing endothelial cell-monocyte adhesion by means of  
an increase in the expression of  ICAM-1 and VCAM-1. (J Vasc Surg 1997;25:866-76.) 
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Despite continued research in vascular disease, there 
are many questions regarding the underlying patho- 
genesis that remain unanswered. Current surgical 
techniques, including endovascular stents and angio- 
plasty, remain plagued by the problem of  restenosis, 
which may occur from 1 month to 1 year in as many 
as 30% to 50% of  patients. * The molecular mecha- 
nism of  both atherosclerosis and restenosis is com- 
plex. Some of  the answers to the pathogenesis, and 
therefore potential therapy, may lie at the molecular 
level. 
Manipulation of  growth factors and cytokines 
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may provide the key to understanding why normal 
healing of the vascular wall leads to a pathogenic 
process. In the pathogenesis ofatherosclerosis, a cru- 
cial initial step in the formation of a lesion is the 
recruitment of the monocyte to the vascular wall. 2 
The adhesion cascade, involving members of the 
immunoglobulin superfamily, selectins, and inte- 
grins, plays a vital role in this process,  The precise 
signals, mediators, and inhibitors continue to be bet- 
ter defined. 4 This process of increased adhesion is 
most important in the postinjury state, such as after 
endarterectomy or angioplasty, when the influx of 
leukocytes and subsequent production of multiple 
growth factors occurs, s Growth factors, including 
tumor necrosis factor-c~ (TNF-cQ and interleukin 113 
(IL-I~), influence this process by upregulation of 
cell adhesion molecules (CAMs). 6 The first portion 
of the present study involves an evaluation of CAM 
expression on human vascular disease specimens. 
Recently, insulin-like growth factor-1 (IGF-1), a 
smooth muscle cell mitogen, was found to be locally 
increased for several weeks after vascular injury in a 
rat model, which suggests its role as an important 
regulator of the arterial wall's response to  injury. 7 10 
IGF-1 has been shown to promote the migration and 
tube-forming activity of endothelial cells, supporting 
its role as a stimulant after vascular injury. 11 The 
potential role of IGF-1 in intimal hyperplasia stimu- 
lated our interest in its role in monocyte-endothelial 
interaction. We have studied its effect in monocyte- 
endothelial dhesion and the expression of CAMs to 
determine its influence in the early/late atheroscle- 
rotic or restenotic lesion. 
MATERIALS AND METHODS 
Tissue collection and preparation. To examine 
the presence of CAMs on human vascular disease 
specimens, an immunohistochemieal analysis of 25 
diseased specimens and nine control specimens was 
performed. The atherosclerotic vessels were collected 
at the time of surgery; the specimens included 10 
aortas, 10 carotid arteries, and five peripheral arterial 
vessels. Control specimens were tal~en from normal, 
nondiseased aortas at the time of organ donation. 
Within 5 to l0 minutes after tissue collection, all 
specimens were placed in 4% paraformaldehyde in 
diethyl pyrocarbonate (DEPC)-treated phosphate- 
buffered saline solution (PBS) for 2 hours and then 
transferred to 30% sucrose in DEPC-treated PBS 
overnight. The specimens were cut into 5 mm sec- 
tions, fixed in embedding medium, and frozen in 
liquid nitrogen. Six-micrometer sections were sliced 
on a cryostat machine and placed on a 0.01% poly-L- 
lysine slide, dried for 30 minutes at room tempera- 
ture, and fixed in a solution of 4% paraformaldehyde 
and 2% acetic acid for 15 minutes. 
Immunohistochemical preparation. One slide 
was used for hematoxylin and eosin staining. The 
remaining slides were then rinsed twice with PBS and 
treated with 10% normal bovine serum albumin for 1 
hour to suppress nonspecific binding of immuno- 
globulins. The sections were then washed twice in 
PBS and incubated in 0.3% hydrogen peroxide in 
methanol for 30 minutes to block endogenous per- 
oxidases. After a wash, they were incubated in diluted 
normal blocldng serum that was prepared from the 
species in which the secondary antibody was made. 
The excess was blotted, and the cells were incubated 
overnight at 4 ° C with primary antibodies to intra- 
cellular adhesion molecule-1 (ICAM-1), vascular cell 
adhesion molecule- 1 (VCAM- 1), E-selectin, P-selec- 
tin, and IGF-1 receptor (dilution 1:100; Upstate 
Biotcchnology, Lake Placid, N.Y.). One section was 
stained with antibody to yon Willebrand's factor to 
ensure that the endothelium was intact. If the endo- 
thelium was denuded, the specimen was not used in 
the study. The cells were then washed in PBS, treated 
with biotinylated secondary antibody, and labeled 
with vectastain elite avidin biotin complex reagent 
(Vector Laboratories, Burlingame, Calif.). The slides 
were incubated in peroxidase substrate solution for 
10 minutes, rinsed in tap water, counterstained, and 
mounted. 
Immunohistochemical analysis. All slides were 
viewed in a blinded fashion by two observers using a 
Nikon microscope at a magnification of 100×. We 
examined the luminal side of each vessel. The expres.- 
sion of the CAMs and IGF-1 receptor was assessed 
by a semiquantitative method in which endothelial 
staining was graded on a scale of 0 to 4 in 0.5 
increments according to its extent and intensity: 0, 
no detectable staining of endothelial cells; 1, focal 
and weak staining of cells (i.e., not all endothelial 
cells in a given tissue section are stained, with almost 
1/4 to 1/2 of cells displaying weak positive staining); 2, 
weak staining of most cells; 3, moderate staining of 
most cells; 4, strong staining of all cells. 
HUVEC cell culture. Human umbilical vein 
endothelial cells (HUVECs) that tested negative for 
hepatitis B and human immunodeficiency virus DNA 
were purchased from Clonetics Corporation (San 
Diego) and plated onto T-75 flasks and cultured in 
endothelial cell growth media (Clonetics) containing 
epidermal growth factor, hydrocortisone, bovine 
brain extract, fetal bovine serum, gentamycin, and 
amphotericin B at 5% CO 2 and 37 ° C. The cells were 
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grown to confluence and used in passages three and 
four. HUVECs were harvested by 0.01% trypsin/ 
ethylenediamine tetraacetic acid (EDTA) solution 
(Life Technologies, Grand Island, N.Y.), neutral- 
ized, and then grown to confluence in96-well plates 
for use in adherence assays. The remaining cells were 
passaged into T-75 flasks, where they were treated 
with IGF-1 (Sigma Chemical Company, St. Louis) at 
a dose of 150 ng/ml and TNF-c~ at 100 U/ml 
(Sigma) for varying times, harvested, and counted. 
Some of these IGF-1-treated cells were subsequently 
lysed for use in Western blotting. Cells were counted 
and separated into equal aliquots before lysing to 
ensure the same amount in each sample. A protein 
assay (Bio-Rad Laboratories, Richmond, Calif.) was 
performed before subjecting the samples to sodium 
dodecylsulfate polyacrylamide gel electrophoresis 
(SDS-PAGE). 
Monocyte separation. First, 120 ml of blood 
was collected from young, healthy, nonsmoking vol- 
unteers into plastic tubes containing 2% EDTA. Red 
blood cells were sedimented using 6% dextran for 1 
hour. The plasma was layered over a 1.067 gradient 
(Accurate Chemicals, Westbury, N.Y.) and centri- 
fuged at 300g. The gradient containing the cells was 
removed, and the cells were washed with a solution 
containing 0.9% NaC1, 0.13% EDTA, and 1% bovine 
serum albumin (BSA). This solution was spun at 
600g for 7 minutes. The supernatant was discarded, 
and the cells were washed again in the same solution. 
The cells were then layered over EDTA plasma nd 
centrifuged toremove the platelets. The supernatant 
was discarded, and the cells were resuspended in 5% 
dextrose in Hanl~s' balanced salt solution (HBSS). 
Cells were counted and assessed for viability and 
purity. Greater than 90% of cells were monocytes, 
with 95% viability as determined by trypan blue dye 
exclusion. 
Adherence assay. These assays were carried out 
by the method previously described by our laborato- 
ry. 12-~4 Briefly, the monocytes were labeled with 
Sichromium-sodium chromate (DuPont Medical 
Products, Boston) for 1 hour at 37 ° C and 5% CO 2 
with continuous agitation. The cells were then cen- 
trifuged and washed twice with HBSS. Monocytes 
(100,000 cells) were plated per well on two 96-well 
plates for 1 hour. These well plates that contained 
confluent HUVECs were treated with IGF-1 in vary- 
ing doses in one setup of experiments and varying 
times in another before incubation with monocytes. 
The monocyte-endothelial cell bilayer was incubated 
for 1 hour at 5% CO2. The wells were washed with 
Rosewell Park Memorial Institute (RPMI) 1640 me- 
dium twice and then swabbed. The swabs were 
placed in scintillation vials and counted on a Beck- 
man gamm a counter. 
Western blot analysis. Acrylamide (10%) mini- 
gels (Novex, San Diego) were loaded with 30 btg of 
protein from each sample. In a separate lane, a col- 
ored methylated marker was run to determine mo- 
lecular weight. The gels were run at 30 mA for 3 
hours. Gels were transferred onto 0.2 ~mol/L nitro- 
cellulose paper overnight at 40 V constant and then 
incubated with 5% powdered milk (Nestle Foods, 
Glendale, Calif.) in PBS containing 0.05% Tween-20 
for 1 hour as a blocking step. The blot was washed 
twice with PBS-Tween and then incubated in pri- 
mary antibody of either ICAM- 1, VCAM- 1, P-selec- 
tin, or E-selectin (l:100) (Becton-Dickinson Immu- 
nocytometry s stems, San Jose, Calif.) for 2 hours. 
The blot was washed three times and incubated in 
secondary antibody of goat antimouse horseradish 
peroxidase conjugate (1:2000) for 1 hour. The blot 
was washed again and then placed in enhanced 
chemiluminescent (ECL) reagents (Amersham, Ar- 
lington Heights, Ill.) for 1 minute. Finally, the blot 
was exposed to Kodak X-omat autoradiography film 
(Eastman Kodak, Rochester, N.Y.) for 5 minutes. 
Flow cytometry. HUVECs were treated at con- 
fluence in T-75 flasks with 150 ng/ml of IGF-1 for 2 
hours to 24 hours. Cells were treated with trypsin/ 
EDTA, scraped, and centrifuged. The supernatant 
was discarded, and ceils were resuspended in 1% BSA 
in PBS and divided into 4 equal aliquots of approxi- 
mately 500,000 cells each. Each tube was used for a 
different antibody, including phycoerythrin (PE)- 
conjugated ICAM-I, PE-conjugated P-selectin, and 
anti-VCAM-1, and anti-E-selectin (Becton-Dickin- 
son). These vials were gently shaken to ensure com- 
plete mixing and then incubated for 1 hour on ice at 
4 ° C. The cells were then pelleted and washed with 
0.5% BSA and 0.1% sodium azide in PBS and centri- 
fuged again at 1000 rpm for 5 minutes. The cells 
incubated with the primary antibodies of VCAM-1 
and E-selectin were then incubated with fluorescein 
isothiocyanate (FITC)-labeled goat antimouse sec- 
ondary antibody for I hour on ice. Unbound FITC~ 
labeled antibody was removed by washing the cells 
twice in BSA/sodium azide/PBS. All cells were fixed 
in 2% paraformaldehyde before analysis. A control 
group that consisted of cells treated only with sec- 
ondary antibody and unstained cells was used. All 
groups were analyzed in a FACStar PLUS flow cy- 
tometer (Becton Dickinson). Background fluores- 
cence was determined with PBS-containing, unla- 
beled HUVECs. HUVEC samples from various 
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Fig. 1. Dose-response effect of IGF-1 on monocyte adherence to HUVECs incubated with 
various doses oflGF-1 for 4 hours. Values are mean _+ SEM. n = 7. *p < 0.01. 
groups were run with the FITC photomultiplier ad- 
justed to a high voltage such that the fluorescence 
histogram derived from the forward angle versus ide 
scatter-gated HUVEC population yielded a small 
background (<5%) autofluorescence intensity in the 
range reserved for positively FITC-stained cells. For 
each sample, log fluorescence data from 10,000 cells 
were collected. The percent positive and the mean 
channel fluorescence were determined for each sam- 
ple. 
Data analysis. For the adherence studies, data 
are presented as the mean + SEM. Differences in 
monocyte-HUVEC adherence were analyzed using 
one-way analysis of variance and were considered 
statistically significant if the p value was less than 
0.05. Statistical analysis of the immunohistochemical 
data was performed using the Kruskal-Wallis non- 
parametric analysis of variance test and subsequently 
compared using Dunn's multiple comparison test- 
ing. Agreement between the two observers on the 
amount of staining was >90%. The mean of the two 
readings was used for statistical nalysis. 
RESULTS 
Upregulation of  binding of monocytes to 
IGF-1 stimulated HUVECs.  HUVECs grown to 
confluence on 96-well plates and treated with IGF-1 
for 4 hours showed a significant increase in binding 
to monocytes collected from the blood of young, 
healthy nonsmoking volunteers. To establish the op- 
timum concentration of IGF-1 that stimulated ad- 
herence, a dose-response experiment was performed. 
Exposure of endothelial cells to 0.875 to 200 ng/ml  
was done. There was a dose-dependent effect, with a 
statistically significant difference in adherence start- 
ing at the dose of 20 ng/ml,  with peal¢ adherence 
occurring at 150 ng/ml  (Fig. 1). A time course of 
this adherence was done with four experiments in 
which HUVECs were incubated for 30 minutes to 
24 hours with a dose of 150 ng/ml  of IGF-1. This 
revealed an increase of adherence starting at 30 min- 
utes and increasing to a maximum at 4 hours of 45% 
over baseline (Fig. 2). HUVECs treated with TNF-cx 
(100 U/ml)  were used as a positive control in this 
experiment, significantly increasing adherence at 4 
hours. This is consistent with previously published 
literature on the effect of TNF-c~ on endothelial 
cells) s 
To show that the effect of IGF-1 was specific to 
the activation of the known IGF-1 receptor, 
HUVECs were incubated with IGF-1 receptor anti-- 
body (dilution 1:50) for 30 minutes before the addi- 
tion of IGF-1 (150 ng/ml).  The IGF-1 receptor 
antibody significantly inhibited the increase in 
monocyte adhesion in response to IGF-1 (Fig. 3). 
To analyze the mechanism of this increased adher- 
ence, tyrosine ldnase inhibitors genistein (100 
I~mol/L) and herbimycin-A (0.875 Ixmol/L) were 
added to each cultured well of HUVECs for 15 
minutes before the addition of IGF-l(150 ng/ml)  
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Fig. 2. Kinetics of IGF-l- induced increased monocyte adherence to HUVECs. Percent in- 
crease over baseline monocyte adherence fin absence of IGF-1 was calculated. Values are 
mean +_ SEM. n = 4. *p < 0.01. 
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Fig. 3. Effect of IGF-1 in presence and absence of IGF-1 receptor antibody on monocyte 
adherence to HUVECs. HUVECs were incubated with IGF-1 receptor antibody (dilution 
1:50) for 15 minutes before incubation with IGF-1 at 150 ng/ml. Values are mean + SEM. n = 4. 
and incubated for 4 hours. This showed an attenua- 
t ion in the increased adhesion to baseline levels (Fig. 
4). The addit ion o f  TNF-c~ (100 U/ml )  and endo- 
thelin-1 (ET-1; 1 × 10 _7 mol /L )  to HUVECs  both 
with and without IGF - I  at a dose of  150 ng /ml  was 
performed. A statistically significant increase in the 
adherence o f  each mediator  alone was demonstrated.  
The addit ion of  IGF-1 resulted in an additive rather 
than synergistic effect between these mediators (data 
not  shown). 
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Fig. 5. Time course of ICAM-1 expression of HUVECs treated with IGF-1 (150 ng/mi) as 
detected by immunoblotting with ICAM-1 antibody (dilution 1:1000). T, HUVECs treated 
with TNF-c~ (100 U/ml) for 4 hours used as a positive control. B, Baseline untreated HUVECs. 
Data are representative of three experiments. 
Western blott ing analysis o f  IGF - l - t reated  
HUVECs .  T-75 flasks of confluent HUVECs were 
treated for 30 minutes to 24 hours with IGF-1 at 
150 ng/ml .  These cells were then passaged, 
counted, and divided such that each sample con- 
tained the same number of cells, then lysed and run 
on a 10% acrylamide gel. Immunoblott ing with 
CAM antibodies demonstrated a distinct increase in 
ICAM-1 starting at 2 hours and continuing to 4 and 
8 hours (Fig 5). HUVECs treated with TNF-c~ (100 
U/ml )  for 4 hours were used as a positive control 
and showed a distinct increase in ICAM-1 expres- 
sion. A small increase in VCAM-1 expression was 
also noted at 2 and 4 hours after the IGF-1 treatment 
(Fig. 6). No P-selectin or E-selectin was detected in 
baseline or IGF-1-treated cells, as observed by West- 
ern blotting. 
Flow cytometry o f  IGF - l - t reated  HUVECs .  
To better quantify the changes in CAM expression 
that occur in response to IGF-1, flow cytometric 
analysis using antibodies to ICAM-1, VCAM-1, E- 
selectin, and P-selectin was completed. ICAM-1 was 
constitutively expressed and was markedly upregu- 
lated by IGF-1 in HUVECs at 4 hours of treatment, 
as assessed by flow cytometry (Fig. 7). The mean 
fluorescence intensity of ICAM-1 antibody in the 
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Fig. 6. Time course of VCAM-1 expression of HUVECs treated with IGF-1 (150 ng/ml) as 
detected by immunoblotting with VCAM- 1 antibody (dilution 1:1000). B, Baseline untreated 
HUVECs. Data are representative of three experiments. 
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Fig. 7. Analysis of surface expression of ICAM-I (A), VCAM-1 (B), E-selectin (C), and 
P-selectin (D) on HUVECs incubated with IGF-1 (150 ng/ml) for 4 hours by flow cytometry. 
X axis represents fluorescence intcnsity, and Y axis represents relative number of cells. 
untreated cells was significantly increased from 2 to 
24 hours after IGF-1 treatment (Fig, 7, A and Fig. 
8). VCAM-1 showed a significant increase at 2 and 4 
hours, correlating well with our Western blot data 
(Fig. 7, B and Fig. 8). E-selectin and P-selectin did 
not show a statistically significant increase in their 
expression i  IGF-]-treated HUVECs (Fig. 7, C and 
D). 
Immunohistochemical  analysis o f  CAMs and 
IGF-1 receptor. Statistical analysis of staining in- 
tensity revealed significant increases in the immuno- 
reactivity of E-selectin and P-selectin (Fig. 9, E and 
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Fig. 8. Mean fluorescence oflCAM-1 and VCAM-1 ex- 
pression on HUVECs at various time periods after treat- 
ment with IGF-1 (150 ng/ml). Values are mean _+ SEM. 
Data represent three experiments. *p < 0.05. 
F), with apvalue less than 0.05. ICAM-1 was present 
in control samples but was significantly increased in 
the diseased specimens (Fig. 9, C; p < 0.05). 
VCAM-1 was minimally present in both control 
specimens and diseased specimens (Fig. 9, D), and 
differences in its expression were not significant. To 
examine the role of IGF-1 in these specimens, tain- 
ing for IGF-1 receptor was performed. In ten athero- 
sclerotic aortic samples, significant staining (2 to 3 +) 
was present (Fig. 10). Out of five control specimens, 
one demonstrated minimal (1 +) staining of IGF- 1 
receptor antibody (p < 0.05). 
DISCUSSION 
At sites of both atherosclerosis and intimal hyper- 
plasia, CAMs play an important role in monocyte 
endothelial adhesion and subsequent lesion forma- 
[ion) 6 Members of the integrin, immunoglobulin, 
and selectin families act in the initial rolling of the 
leukocyte, firm adhesion, and diapedesis into the 
extravascular space. 16 Endothelial cells and leuko- 
cytes are responsible for the production of cytoldnes 
and growth factors that subsequently activate ndo- 
thelial cells and smooth muscle cells. Mediators in- 
cluding TNF-0~, IL-1, and ET-1, which are known to 
be present at sites of vascular injury, have also been 
shown to increase monocyte-endothelial interaction, 
indicating a multifactorial impact on lesion forma- 
tion. 15,17,18 Previously published reports have dem- 
onstrated the proliferative ffects of IGF-1 after en- 
dothelial denudation r,9 and thus support its role in 
the pathogenesis of atherosclerosis and restenotic 
lesions of intimal hyperplasia. We proposed that 
IGF-1 may also have an earlier ole in the cascade of 
pathologic events resulting in atheroma nd intimal 
hyperplasia. We postulated that IGF-1 may increase 
Fig. 9. Immunoreactivity of representative atheroscle- 
rotic aorta specimen stained with the following primary 
antibodies: Immunoglobulin G isotype control (A), yon 
Willebrand's factor (B), ICAM-1 (C), VCAM-1 (D), E- 
selectin (E), and P-selectin (F). Specimens were then incu- 
bated in biotinylated secondary antibody and stained with 
immunoperoxidase. 
the adherence ofmonocytes toperturbed endothelial 
cells. 
Our studies show that IGF-] increases mono- 
cyte-endothelial cell adherence, with the maximal 
increase in adherence (45% over baseline) occurring 
at 4 hours at a dose of 150 ng/ml.  In human beings 
the production of IGF-1 is complex, and the full 
systemic and local factors that affect its production 
are still being discovered. Normal adult levels of 
IGF-1 range from 20 to 50 ng/ml.  However, in 
certain conditions, IGF-1 levels may reach serum 
levels greater than 200 ng/ml.  IGF-1 is produced by 
a variety of tissues, including the endothelial cell, and 
may be acting in a paracrine or autocrine manner 
after injury to the vascular wall) ° At the site of the 
vascular injury, the local tissue concentrations of 
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Fig. 10. Treatment with IGF-1 receptor primary antibody with secondary biotinylated anti- 
body and peroxidase staining of a control aortic specimen (A) and an atherosclerotic aortic 
specimen (B). 
both IGF-1 and IGF-1 messenger RNA have been 
shown to be increased. 7,9 The effect of  these in- 
creased concentrations on the endothelium remains 
to be established. In addition, multiple IGF-1 bin& 
ing proteins exist that may be altering the availability 
of IGF-I at these sites of vascular injury) 9 These 
binding proteins may be responsible for potentiating 
or inhibiting the action of IGF-1. 2° Mthough there 
were no exogenously added IGF-1 binding proteins 
in our system, we realize they may be produced from 
the endothelial cells and may play a role in the activ- 
ity of IGF-1. 
To confirm that IGF-1 was playing a specific role 
in the induction of leukocyte adherence, the endo- 
thelial cells were treated with IGF-1 receptor anti- 
body before stimulation with IGF-1. This antibody 
treatment attenuated the increase in leukocyte ad- 
herence, confirming that IGF-1 was playing a spe- 
cific, receptor-mediated role. In our atherosclerotic 
plaque specimens, an increase of IGF-1 receptor ex- 
pression was found when compared with control 
specimens, providing strong circumstantial evidence 
that this peptide has a role in the formation of  the 
atherosclerotic lesion. 
Next, we evaluated the signal transduction path- 
way involved in IGF-l-stimulated increased mono- 
cyte-endothelial dhesion. Previous studies in our 
laboratory have shown that blockade of increased 
adhesion induced by ET-1 was attenuated with the 
use of tyrosine kinase inhibitors. 17,21 Knowing that 
IGF-I acts on cells through a tyrosine ldnase-medi- 
ated mechanism, we speculated that this may be 
involved in the increase in adhesion that was demon- 
strated. Our studies with IGF-1 showed an attenua- 
tion in adherence after treatment with genistein and 
herbimycin-A, broad spectrum tyrosine kinase inhib- 
itors. Genistein is a competitive inhibitor of  adeno- 
sine triphosphate in the ldnase reaction, whereas her- 
bimycin A produces an irreversible blockade of the 
src and epidermal growth factor receptor families of 
ldnases. 22 Although inhibiting tyrosine kinase activa- 
tion by different mechanisms, genistein and herbimy- 
cin-A both attenuated equally the IGF-l- induced 
increased monocyte adhesion, suggesting that both 
are equally efficacious at the 4-hour time period of 
incubation. It is possible that a different mechanism 
of action is present in the early time period. Ongoing 
studies in our laboratory will further define the dif- 
ferent mechanisms of action of these agents, as well 
as the signal transduction pathway involved in IGF- 1 
stimulation of HUVECs. 
Having shown that IGF-1 upregulates monocyte 
adherence to endothelial cells, we hypothesized that 
this increase in adherence was secondary to IGF-I 's 
induction of CAM expression by the stimulated en- 
dothelial cells. On the endothelial cell surface, we 
observed a distinct increase in ICAM-1 expression 4 
hours after IGF- i  stimulation, as measured by both 
flow cytometry and Western blotting. ICAM-1 ex- 
pression by Western blotting showed an increase 
after IGF-1 treatment starting at 2 hours and con- 
tinuing to 16 hours. With flow cytometry, a signifi- 
cant increase in ICAM-1 expression was noted from 
2 to 24 hours after stimulation, which correlated well 
with our adhesion studies. A smaller increase in 
VCAM- 1 expression was noted after 2 and 4 hours of 
treatment. In other cell systems, the level of ICAM-1 
stays constant after stimulation by known inflamma- 
tory mediators, with levels remaining high at 24 
hours. 17 In our study, we observed a decrease of 
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ICAM-1 and VCAM-1 expression as well as adher- 
ence after a peak o f  4 hours. This finding suggests 
that CAM expression is regulated by several mecha- 
nisms that could be cell-specific, stimulus-specific, or
both. 
In increased leukocyte-endothelial cell interac- 
tion, not only could an increase in the expression of  
CAMs be important, but an activated state of  CAMs 
could be critical. This may explain the discrepancy in 
terms of  the ldnetics o f  increased monocyte adhesion 
versus the ldnetics o f  increased expression of  CAMs 
as observed by Western blotting and flow cytometry. 
Activation of  CAMs may involve changes in intracel- 
lular pH,  calcium, phosphoinositide, or protein ld- 
nases. The extracellular and intracellular domains 
may undergo some conformational change on activa- 
tion to make these molecules more  sensitive to their 
respective ligands. At this point, we do not know the 
exact mechanism that is involved in IGF- l - induced 
increased expression or activation of  CAMs. Obvi- 
ously, further studies in this area are warranted. 
Our  immunohistochemical staining of  human 
atherosclerotic plaque specimens howed a signifi- 
cant increase in ICAM-1 expression, which corre- 
lated with the data we found after IGF-1 treatment 
o f  endothelial cells. Human atheroma lso showed 
an increase in P-selectin and E-selectin expression in 
the endothelium. This finding supports other studies 
regarding the presence of  selectins in peripheral 
atherosclerotic disease specimens. 23,24 The lack o f  
P-selectin and E-selectin in the IGF- l -st imulated 
HUVECs  may be a result o f  limitations o f  perform- 
ing an in vitro study with HUVECs.  IGF-1 may not 
be involved in the induction of  these CAMs. We 
expect that in vivo a number  o f  growth factors in 
addition to IGF-1 are having an independent and 
potentially synergistic effect on the endothelial cell, 
leading to selectin expression. 
One question that must be answered is whether 
IGF-1 increases the transcription, translation, or 
posttranslational modification of  CAMs. In addition, 
the interaction between IGF-1 and other growth 
factors needs to be evaluated to see whether a syner- 
gistic or antagonistic effect exists in vivo. Further 
studies that have been planned by our laboratory 
involve the use of  aortic endothel ium and an animal 
model to evaluate the effects o f  IGF-1 on endothe- 
lium. 
CONCLUSION 
These studies show that IGF-1 enhances the ex- 
pression of  ICAM-1 and VCAM-1,  which results in 
an increase in endothelial cell-monocyte adhesion. 
This occurs through the IGF - I  receptor, whose 
mechanism involves a tyrosine ldnase-modulated in-
tracellular pathway. CAMs are believed to be impor- 
tant in the initial formation and propagation of  both 
the atherosclerotic and restenotic lesion. Further de- 
tailed analysis o f  the signal transduction pathway of  
IGF- l - induced CAM expression may facilitate devel- 
opment of  better pharmacologic and immunologic 
tools to prevent or ameliorate the proliferative pro- 
cesses o f  atherosclerosis and intimal hyperplasia. 
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DISCUSSION 
Dr. Thomas W. Wakefield (Ann Arbor, Mich.). Dr. 
Balaram and colleagues present a very important and ele- 
gantly presented study looldng at the presence of P-selec- 
tin, E-selectin, and the adhesion molecules ICAM-1 and 
VCAM-1 in human vascular disease samples compared 
with normal aortas, along with IGF-1. They found that 
IGF-l is increased after arterial injury and that this factor is 
important for increasing the adhesion of monocytes to a 
layer of HUVECs. This adhesion occurred in a dose-de- 
pendent fashion. In human disease specimens, IGF-1 re- 
ceptors were also increased as compared with control spec- 
imens. Clearly, adhesion molecules are important in the 
pathogenesis of vessel wall inflammation. I have three 
questions. 
First, as P-selectin and E-selectin are usually transiently 
expressed at the beginning of an inflammatory esponse, 
can the authors peculate why they found elevated levels of 
these selectins in the chronic state of arterial disease? What 
stimulus is there for the continued expression of these 
selectins in the absence of an acute inflammatory esponse? 
Second, I would like to know a little bit more about 
the specimens, which were said to be from diseased, ath- 
erosclerotic, and restenotic vessels. I would expect some 
difference in immunohistochemical composition between 
atherosclerotic lesions and restenotic lesions. Were these 
lesions equivalent in their expression of, for example, P- 
selectin or ICAM-1, or are there other important differ- 
ences that can help us understand better the pathophysio- 
logic mechanism of these lesions? 
Finally, in view of the potential interrelationships be- 
tween thrombus and vessel wall, were there any correla- 
tions between those specimens that had high levels of 
adhesion molecules and the presence or absence of lami- 
nated clot along the surface of the vessel wall? 
I congratulate he authors on their novel and unique 
study. Clearly the role of the inflammatory esponse in 
both arterial and venous vessel wall disease is an area that 
needs further investigation. 
Dr. Sandhya K. Balaram. In answer to your question 
regarding the presence of these selectins in the chronic 
atherosclerotic lesion, we looked at 26 atherosclerotic 
specimens, Which included four restenotic specimens, and 
these were compared with nine normal control specimens. 
Using statistical analysis we saw an increased expression of 
ICAM-1, E-selectin, and P-selectin in these specimens. I 
think this finding supports the fact that there is a similarity 
between both atherosclerosis and inflammation and that 
perhaps these lesions represent chronic inflammatory state. 
This is supported by the fact that in many of our specimens 
we did see the presence of leukocytes, which could be 
responsible for producing growth factors and cytokines 
that would increase the selectin expression on the endothe- 
lial cell. 
Regarding differences between restenotic and athero- 
sclerotic lesions, we were also surprised to not see a signif- 
icant difference between the CAM expression on these 
specimens when we compared them. We expected to see 
some difference; however, statistically we did not see any 
definite difference between selectins and CAMs on the 
presence of restenotic and atherosclerotic lesions. 
Lastly, we did not look at the presence ofthrombus as 
related to our CAM expression on our disease specimens. 
However, this brings up a very interesting point and would 
certainly be a good project for the future. 
